Latest news
CAPR Stock Sinks After-Hours: Capricor Launches Legal Fight Over DMD Therapy Rollout Ahead Of FDA Review - stocktwits.comstocktwits.com · Fri, 07 Aug 2026 21:24:04 GMTStockWatch: Capricor Plunges as FDA Panel, Staff Question Effectiveness of Lead Candidate Deramiocel - Genetic Engineering and Biotechnology NewsGenetic Engineering and Biotechnology News · Mon, 03 Aug 2026 00:49:26 GMTCapricor CEO won’t rule out legal action against FDA after negative adcomm - BioSpaceBioSpace · Fri, 31 Jul 2026 07:00:00 GMTCapricor Therapeutics: FDA Advisory Panel Votes 9-3 That Evidence Does Not Support Deramiocel for DMD Cardiomyopathy - TradingViewTradingView · Thu, 30 Jul 2026 20:13:04 GMTFDA Committee Vote Against Approving Capricor’s Deramiocel - Inside Precision MedicineInside Precision Medicine · Thu, 30 Jul 2026 16:46:11 GMTFDA advisors vote no to Capricor's DMD therapy - pharmaphorumpharmaphorum · Thu, 30 Jul 2026 09:10:40 GMTCapricor plummets after FDA panel votes against Duchenne heart disease therapy - ReutersReuters · Thu, 30 Jul 2026 07:00:00 GMTCAPR Stock Eyes Worst Week Ever After FDA Panel Blow To Deramiocel — Retail Bulls Still See A Path To Approval - TradingViewTradingView · Thu, 30 Jul 2026 03:07:00 GMT